Is autoimmune thyroid disease linked to higher rates of autoimmune gastritis and pernicious anemia?

The association between autoimmune thyroid disease (AITD) and autoimmune gastritis (AIG) is a well-documented phenomenon known as the "thyrogastric syndrome." This relationship is a primary example of autoimmune clustering, where the presence of one organ-specific autoimmune disorder significantly increases the likelihood of developing others.

Clinical evidence and prevalence

Extensive clinical research confirms that patients with AITD, particularly Hashimoto's thyroiditis and Graves' disease, have a substantially higher prevalence of AIG and its end-stage manifestation, pernicious anemia (PA).

• Co-occurrence rates: Meta-analyses and observational studies indicate that approximately 10% to 40% of patients with AITD also have AIG. In some cohorts, parietal cell antibodies (PCA)—the hallmark of gastric autoimmunity—are found in over 20% of AITD patients, compared to roughly 2.5% in healthy controls (OR 9.38, 95% CI 6.78–12.98).
• Progression to Pernicious Anemia: AIG leads to the destruction of gastric parietal cells, causing a deficiency in intrinsic factor and subsequent Vitamin B12 malabsorption. Research shows that up to 27% of hypothyroid patients exhibit B12 deficiency, with overt pernicious anemia occurring in approximately 10% to 25% of older AITD patients.
• Bidirectional risk: The association is reciprocal; roughly 40% of patients diagnosed with AIG or PA are found to have concurrent thyroid autoimmunity.

Mechanistic explanations

The clustering of these conditions, formally categorized as Autoimmune Polyendocrine Syndrome type 3B (APS-3B), is driven by shared genetic and developmental factors.

• Shared Embryological Origin: Both the thyroid gland and the gastric secretory cells originate from the endoderm of the primitive foregut. This shared lineage may result in common antigenic targets or similar susceptibility to immune dysregulation.
• Genetic Susceptibility: Strong evidence links both conditions to specific Human Leukocyte Antigen (HLA) genotypes, particularly HLA-DR3, HLA-DR4, and HLA-DR5. Additionally, non-HLA genes involved in T-cell regulation, such as CTLA-4 and PTPN22, are shared risk alleles that lower the threshold for multiple autoimmune "hits."
• Immunological Pathways: Both diseases involve a breakdown in self-tolerance mediated by Th1 and Th17 immune responses. The immune system simultaneously targets thyroid-specific antigens (like thyroid peroxidase) and the gastric H+/K+ ATPase pump (the proton pump), leading to concurrent organ damage.

Clinical implications

Given the high rate of clustering, clinical guidelines suggest a low threshold for screening in patients with established thyroid disease.

• Screening: Patients with AITD should be periodically monitored for Vitamin B12 deficiency and, if symptomatic, screened for parietal cell antibodies.
• Complication Management: Early detection of AIG is critical not only to prevent the neurological and hematological complications of pernicious anemia but also to monitor for long-term risks such as gastric carcinoid tumors and adenocarcinoma, which are more prevalent in patients with chronic AIG.

Bottom line

The association between autoimmune thyroid disease and autoimmune gastritis/pernicious anemia is a scientifically validated example of autoimmune clustering (APS-3B). Patients with AITD face a significantly elevated risk of gastric autoimmunity due to shared genetic predispositions and common embryological origins, necessitating routine clinical vigilance for Vitamin B12 deficiency.